For richer charts and full features, open SpikePanel on desktop.
Graded daily on value A-, growth C-, profitability B, momentum C. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $SNY are available with SpikePanel Pro.
Key events, in time order
CEO cites €15-20B deal capacity, eyes late-stage assets; CMD before year-end
Q3 sales beat on Dupixent strength; FY26 sales and EPS outlook raised
enFuse-based injector approved to administer Sarclisa subcutaneous formulation in multiple myeloma patients
Groundbreaking at BioCampus to expand insulin manufacturing capacity
Oral dual-targeting small molecule to enter pipeline; Phase 1 planned for 2027
Avoids fine but must rectify past marketing practices to address competition concerns
Sanofi pays $1B upfront and up to $7B milestones for 4 long-acting antibodies, boosting inflammation pipeline
Expands indication to infants, strengthening meningococcal prevention and market position
Dupixent tops €5B quarterly sales; new CEO's first address focuses on pipeline revival
Market discusses Sanofi's cash position and potential acquisition of ABVX
Market eyes Sanofi's €14-15B M&A budget for 2026, potential ABVX acquisition
Company restructures top leadership team to focus on business units and strategic execution
Sanofi and Aqemia announced expansion of multi-year research collaboration in small molecule drug invention.
First anticancer treatment via on-body injector, offering new option for multiple myeloma patients
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice